Ron Lanton III, Esq, discusses the revamped version of the Trump Administration’s MFN drug pricing policy and why his second term may yield different outcomes.
Ron Lanton III, Esq
Advertisement
Ron Lanton III, Esq, Partner at Lanton Law PLLC
Articles by Ron Lanton III, Esq
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
Pharmacists Can Play Central Role in Patients’ Infusion Services | ASHP Midyear 2025
2
Women Seek Holistic Interventions for Improving Health Outcomes
3
What TrumpRx Means for Independent Pharmacies and Their Patients
4
Social and Economic Factors Significantly Influence Supply of OTC Antibiotics
5
